Taro Pharmaceutical Industries (TARO)
(Delayed Data from NYSE)
$42.48 USD
0.00 (0.00%)
Updated Apr 30, 2024 04:00 PM ET
After-Market: $42.48 0.00 (0.00%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
TARO 42.48 0.00(0.00%)
Will TARO be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for TARO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TARO
Amicus (FOLD) Banks on Galafold, Overdependence a Concern
Iovance (IOVA) Falls After Clinical Update on Lung Cancer Drug
TARO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Procaps Group, S.A. (PROC) Q3 Earnings and Revenues Top Estimates
Senti Bio (SNTI) Rises as FDA Clears IND for Cancer Candidate
Cidara (CDTX) Up on EC Nod for Rezzayo in Invasive Candidiasis
Other News for TARO
Taro Announces Extraordinary General Meeting and Ordinary Class Meeting of Shareholders for Approval of Merger with Sun Pharmaceutical Industries Ltd.
Taro Pharmaceuticals U.S.A., Inc. Expands OTC Portfolio for Children with the Introduction of bébé Bottoms™ Diaper Rash Crème Spray
Lab says chemical linked to cancer found in acne creams, Bloomberg reports
Estée Lauder, Reckitt fall amid cancer risk in acne treatments
Q2 2021 Taro Pharmaceutical Industries Ltd Earnings Call Transcript